Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ONCY | US
-0.09
-6.67%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.26
1.36
1.37
1.23
Oncolytics Biotech Inc. a development-stage biopharmaceutical company focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep an intravenously delivered immunotherapeutic agent which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary Canada.
View LessPositive Momentum
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
162.2%1 month
156.5%3 months
93.6%6 months
69.9%-
-
7.80
-
-
-1.79
-
-
-36.45M
96.84M
96.84M
-
-
-
-
-138.22
5.43
1.41
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.41
Range1M
0.69
Range3M
0.69
Rel. volume
1.02
Price X volume
1.11M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Assembly Biosciences Inc | ASMB | Biotechnology | 16.59 | 105.27M | -9.05% | n/a | 5.03% |
INmune Bio Inc | INMB | Biotechnology | 5.18 | 102.73M | 1.37% | n/a | 14.65% |
Clearside Biomedical Inc | CLSD | Biotechnology | 1.32 | 101.31M | 14.78% | n/a | -168.27% |
Cue Biopharma Inc | CUE | Biotechnology | 1.68 | 101.15M | 38.84% | n/a | 52.09% |
Marinus Pharmaceuticals Inc | MRNS | Biotechnology | 1.82 | 100.25M | -1.62% | n/a | -202.54% |
Regulus Therapeutics Inc | RGLS | Biotechnology | 1.5 | 98.20M | -4.46% | n/a | 1.45% |
Prelude Therapeutics Incorporated | PRLD | Biotechnology | 1.78 | 97.94M | -6.32% | n/a | 9.99% |
Genenta Science S.p.A | GNTA | Biotechnology | 5.35 | 97.46M | -2.73% | n/a | 0.00% |
Agenus Inc | AGEN | Biotechnology | 4.5 | 97.07M | -2.60% | n/a | -170.56% |
Coherus BioSciences Inc | CHRS | Biotechnology | 0.8758 | 96.93M | -0.80% | n/a | -354.71% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.87 | 94.40M | 1.83% | 5.16 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.22 | 89.04M | -1.80% | 14.48 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.01 | 53.54M | -3.35% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.79 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 7.80 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 93.62 | 72.80 | Riskier |
Debt to Equity | - | -1.23 | - |
Debt to Assets | - | 0.25 | - |
Market Cap | 96.84M | 3.66B | Emerging |